Leadiant Biosciences, Inc.: FDA recalls
Newest recall start date in this list: . Abelcet (Amphotericin B Lipid Complex) Injection, 5 mg/mL, 100 mg vial, Rx only, Manufactured by Exelead, Inc., Indianapolis, IN 46268…
FDA enforcement events from 2018 to 2023; export dated . The recall start date and FDA report date are separate fields. Read the recall classes.
FDA enforcement reports name Leadiant Biosciences, Inc. as the recalling firm in 4 events. The events have 4 product records. The recalls started from 2018 to 2023. All the events are drug recalls. By FDA enforcement events, Leadiant Biosciences, Inc. is number 832 of 1,629 firms that have a page. Events that Leadiant Biosciences, Inc. started: none in 2024 and none in 2025. For all FDA enforcement events, the count rose by 3.6%, from 1,773 in 2024 to 1,836 in 2025.
It is important to note that most of the time recall classifications are determined after the recalling firm provides all of the information needed to determine the risk posed to public health. The classification and posting in the FDA Enforcement Report should not be seen as an expansion or change to a firm’s voluntary public warning.
FDA publishes these words. Source: FDA, Enforcement Reports, Important Note, read on . openFDA export of .
Enforcement events
4 events, newest first.
An event with 1 product record and a class that is not Class I has no page. It has a row in this table.
Enforcement event: All the product records that have one FDA event number. This site shows one event on one page.
Recalling firm: The firm that the FDA record names for a recall.
Follow by RSS:Food, drug and device recallsFDA Class I recalls
Type and class
| Type | Events |
|---|---|
| Drug | 4 |
| Class | Events |
|---|---|
| Class III | 3 |
| Class II | 1 |
- Share of the events of the firm in Class I
- 0%
- Share of all events on the register in Class I
- 18%
- Events with the status Ongoing
- 0
openFDA, about the status: FDA does not update the status of a recall after the recall has been classified according to its level of hazard. As such, the status of a recall (open, completed, or terminated) will remain unchanged after published in the Enforcement Reports.
Source: openFDA, Drug Recall Enforcement Reports, Disclaimer.
Events by year
Official channels
- FDA enforcement reportsThe FDA search of the weekly enforcement reports.
- FDA: recalls, market withdrawals and safety alertsThe recall notices on the FDA site.
- FDA: report a problemThe FDA page that shows where a report about a product goes.
- FDA MedWatchThe FDA safety reporting program for drugs and medical devices.
Cite this page
Recall Register. Leadiant Biosciences, Inc.: FDA recalls. https://recallregister.com/firm/leadiant-biosciences-inc/. Source: openFDA enforcement reports. Data through .
Sources
- Source
- openFDA enforcement reports
- Licence
- CC0 1.0
- Export date
- 10 Nov 2026
- State of the firm address
- MD
The firm name is the spelling in the FDA records. A company with 2 spellings has 2 pages.
A firm with more products can have more recalls. This site does not rate one firm against another. How the register is made. Report an error.
Questions
- Which classes do the FDA recalls of Leadiant Biosciences, Inc. have?
- Class III: 3 events. Class II: 1 event. The class is for the product of a recall. It is not a class of the firm.
- What is the newest FDA recall of Leadiant Biosciences, Inc.?
- FDA event 91643, which the firm started on 3 Feb 2023. The first product in the record is:
Abelcet (Amphotericin B Lipid Complex) Injection, 5 mg/mL, 100 mg vial, Rx only, Manufactured by Exelead, Inc., Indianapolis, IN 46268; Distributed by Leadiant Biosciences, Inc., Gaithersburg, MD 20878, NDC 57665-101-41
- How many FDA recalls of Leadiant Biosciences, Inc. have the status Ongoing?
- No event has the status Ongoing in the openFDA file. openFDA says about the status:
FDA does not update the status of a recall after the recall has been classified according to its level of hazard. As such, the status of a recall (open, completed, or terminated) will remain unchanged after published in the Enforcement Reports.